STX5

Across TCGA pan-cancer cohorts, STX5 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of STX5’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where STX5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types STX5 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LIHC, THCA, and KICH are the cancer types where STX5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STX5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.799	<.001	9	view →
THCA	Male	III,IV	−0.550	<.001	9	view →
KICH	Female	All	−0.834	<.001	8	view →
HNSC	Male	III,IV	+0.609	<.001	8	view →
KIRC	Female	All	+0.362	<.001	5	view →
COAD	All	II,III,IV	+0.200	.006	5	view →
STAD	All	II,III,IV	+0.365	.013	4	view →
CHOL	All	All	+0.964	<.001	3	view →
PAAD	Female	All	+0.169	.016	2	view →
ESCA	Female	All	+0.713	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

STX5–LIHC

Open the LIHC breakdown →